Eleven Chinese healthcare and biotech companies filed for IPOs in Hong Kong at the end of September 2025.

The applicants include We Doctor Holdings, Sichuan Biokin Pharmaceutical, and cancer drug maker Betta Pharmaceuticals.

Other IPO seekers are Anhui Huaheng Biotechnology, Annoroad Gene Technology, Binhui Biopharmaceutical, Good Doctor Cloud Healthcare, Shanghai Synyi Medical Technology, Changchun High-Tech Industry, Shaanxi Micot Pharmaceutical, and Yantai Lannacheng Biotechnology.

In total, 23 healthcare and life sciences firms applied for listings in September 2025, with most focused on drugs and medical devices.

The Hang Seng Biotech Index has risen 109% this year, while company earnings show mixed results, with We Doctor and Biokin both reporting losses.

🔗 Source: South China Morning Post